Printed From:


  seeing is believing

The FIRST BIOLOGIC for adults with moderate-to-severe
ATOPIC DERMATITIS who are candidates for systemic therapy3

Click here to see videos from experts in the field discussing atopic dermatitis and the mind, the unmet need and key DUPIXENT trial data

Rapid and sustained improvement compared to baseline in:
  • Lesion extent and severity1,4,5
  • Pruritus intensity1,5
  • Quality of life measures1,5,6
Long-term tolerability profile investigated up to 52 weeks:
  • Discontinuation rates due to adverse events were below 2% in clinical trials3
  • No monitoring for organ toxicities required3

NOW with NICE Technology Appraisal
Guidance (TA534)7 and SMC advice8

Click here to read more

NICE, The National Institute of Health and Care Excellence; SMC, Scottish Medicines Consortium.


1. Blauvelt A, et al. Lancet. 2017;389(10086):2287-2303. 2. Paller A, et al. Poster presented at the 77th annual meeting of the American Academy of Dermatology; 2019; March 1–5: Washington, DC, USA. Poster 10051. 3. DUPIXENT Summary of Product Characteristics. 4. Simpson EL, et al. New Engl J Med. 2016;375(24):2335–2348. 5. De Bruin-Weller, et al. Br J Dermatol. 2017;178:1083–1101. 6. Sanofi Data on File. SAGB.DUP.17.09.1126. September 2017. 7. © NICE [2018] Dupilumab for treating moderate to severe atopic dermatitis. Available from: All rights reserved. Subject to notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication. 8. Scottish Medicines Consortium. Dupilumab (Dupixent). Available from: